3 Pharma stocks in which mutual funds bought up to 7.2% stake; Do you own any?3 Pharma stocks in which mutual funds bought up to 7.2% stake; Do you own any?

Introduction:

Mutual funds were active in the pharma space during Q1 FY26. They picked up stakes of up to 7.2% in three listed companies. These fresh entries have caught the market’s eye.

In the stock market, mutual funds pool money from investors and invest in shares. These funds are managed by professionals. When mutual funds buy a large stake, it shows they believe in a company’s future.

Also Read: Healthcare stock jumps 5% after its net profit increases by 56.8% YoY

Sai Life Sciences

On August 8, 2025, Sai Life Sciences Ltd opened at ₹805.00, up 1.76% from its previous close of ₹791.10. The stock reached a high of ₹864.70 and a low of ₹805.00. By 4:00 PM, it traded at ₹828.15, a 4.68% increase, with a market cap of ₹17,265.73 crore.

Mutual funds increased their holding in Sai Life Sciences Ltd to 3.25% in the June 2025 quarter, indicating a notable rise in institutional interest.

Sai Life Sciences Ltd (NSE: SAILIFE), founded in 1999, is a Hyderabad-based CRDMO serving global pharma and biotech firms. It offers discovery, development, and manufacturing solutions across key therapeutic areas, including oncology.

Biocon

On August 8, 2025, Biocon Ltd opened at ₹358.55, down 1.66% from its previous close of ₹364.60. The stock reached a high of ₹365.70 and a low of ₹341.05. By 4:00 PM, it traded at ₹343.35, a 5.83% decline, with a market cap of ₹45,904.65 crore.

Mutual funds raised their stake in Biocon Ltd to 6.47% during the June 2025 quarter, marking a significant shift in institutional shareholding.

Biocon Ltd (NSE: BIOCON) is a leading biotechnology company manufacturing biosimilars and offering research services. It has a global presence in over 120 countries and ranks among the top biosimilar producers worldwide.

Also Read: Defence stock in focus after company to transfer its defence business to Kalyani Strategic Systems for ₹4,533 Mil

Acutaas Chemicals

On August 8, 2025, Acutaas Chemicals Ltd opened at ₹1,279.45, down 1.17% from its previous close of ₹1,294.65. The stock reached a high of ₹1,303.40 and a low of ₹1,275.10. By 4:00 PM, it traded at ₹1,280.20, a 1.12% decline, with a market cap of ₹10,480.86 crore.

Mutual funds increased their holding in Acutaas Chemicals Ltd to 7.19% during the June 2025 quarter, reflecting a notable change in institutional ownership.

Acutaas Chemicals Ltd (NSE: ACUTAAS), formerly Ami Organics, is a leading R&D-driven specialty chemicals manufacturer. It produces advanced pharmaceutical intermediates, APIs, and materials for agrochemicals and fine chemicals.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs

Q: Which three pharma stocks did mutual funds buy up to 7.2% stake in Q1 FY26?

A: Sai Life Sciences, Biocon, and Acutaas Chemicals saw mutual funds increase their stakes up to 7.2%.

Q: What does mutual fund buying large stakes in pharma stocks indicate?

A: It signals professional confidence in the companies’ growth potential and future prospects.

Q: How do mutual funds operate in the stock market?

A: Mutual funds pool investor money and invest it professionally across various stocks, including pharma companies.